Factors associated with the inflammatory immune response induced by COVID-19 vaccines among adults

Abstract :

In efforts to counteract the COVID-19 pandemic, several vaccines have been developed. Despite their efficacy, they are not without adverse immune reactions that may occur among populations according to various factors. The purpose of this study was to explore some factors that are associated with the inflammatory immune response induced by COVID-19 vaccines among the Libyans. This analytical study was performed on recorded data for 410 individuals who received three different COVID-19 vaccines (Sinovac, AstraZeneca-Oxford and Sputnik-V) that were retrieved from the previous study on December 2nd, 2023. Among 410 Libyan adults, 404 cases were enrolled for the final analysis, 56.7% (CI 95%, 52.0-61.1) of the vaccinated experienced systemic inflammatory reactions. Wherein, Sinovac vaccine recipients were more likely to experience inflammatory reactions compared to AstraZeneca-Oxford vaccine recipients with a high significant (2MH=38.344, P<0.001) adjusted odds ratio equal to 5.234 (CI 95%, 3.034-9.029). After controlling for confounding factors, age, gender and comorbidity were found to significantly associated risk factors with an inflammatory response among AstraZeneca-Oxford vaccine recipients (P< 0.001, P=0.021 and P=0.002, respectively). Whereas comorbidity was only one of the significantly increased risk factors associated with the occurrence of inflammatory events among Sinovac vaccine recipients (2=7.507, P=0.006). In conclusion, age, gender, comorbidity and type of vaccine were found to be significant risk factors for the occurrence of inflammatory events induced by vaccines. Further studies with larger sample size and the inclusion of laboratory parameters such as C-reactive protein and alpha-1-acid glycoprotein along with antibodies are needed.

References

1. Heinz FX, Stiasny K (2021) Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 6 (1): 1-13. doi: 10.1038/s41541-021-00369-6
2. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Borisevich SV, Naroditsky BS, Gintsburg AL (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 396 (10255): 887-897. doi: 10.1016/S0140-6736(20)31866-3
3. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, Munster VJ (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 586 (7830): 578-582. doi: 10.1038/s41586-020-2608-y
4. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 397 (10269): 99-111. doi: 10.1016/S0140-6736(20)32661-1
5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova AG, Ozharovskaya TA, Zyranov SK, Borisevich SV, Ginsburg AL (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 397 (10275): 671-681. doi: 10.1016/S0140-6736(21)00234-8
6. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin S-W, Li Y, Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HCJ (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. Journal of Virology. 81 (12): 6594-6604. doi: 10.1128/jvi.02497-06
7. Lasaro MO, Ertl HCJ (2009) New insights on adenovirus as vaccine vectors. Molecular Therapy. 17 (8): 1333-1339. doi: 10.1038/mt.2009.130
8. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker L-G, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 29 (32): 5203-5209. doi: 10.1016/ j.vaccine.2011.05.025
9. Fausther-Bovendo H, Kobinger GP (2014) Pre-existing immunity against Ad vectors. Human Vaccines and Immunotherapeutics. 10 (10): 2875-2884. doi: 10.4161/hv.29594
10. Capone S, D’Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A (2013) Development of chimpanzee adenoviruses as vaccine vectors: Challenges and successes emerging from clinical trials. Expert Review of Vaccines. 12 (4): 379-393. doi: 10.1586/erv.13.15
11. Hotez PJ, Bottazzi ME (2022) Whole inactivated virus and protein-based COVID-19 vaccines. Annual Review of Medicine. 73 (1): 55-64. doi: 10.1146/annurev-med-042420-113212
12. Hadj Hassine I (2021) COVID-19 vaccines and variants of concern: Reviews in Medical Virology. 32 (4): 1-16. doi: 10.1002/rmv.2313
13. Khoshnood S, Arshadi M, Akrami S, Koupaei M, Ghahramanpour H, Shariati A, Sadehifard N, Heidary H (2022) An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. Journal of Clinical Laboratory Analysis. 36 (5): 1-12. doi: 10.1002/jcla.24418
14. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Jingxin L, Yang M, Song Y, Wang X, Gao Q, Zhu F (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21 (2): 181-192. doi: 10.1016/S1473-3099 (20)30843-4
15. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Gue J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X (2020) Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Journal of the American Medical Association. 324 (10): 951-960. doi: 10.1001/ jama.2020.15543
16. Dyer O (2021) COVID-19: Chinese vaccines may need changes to improve efficacy, admits official. The British Medical Journal. 373: n969. doi: 10.1136/bmj.n969
17. Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines-a new era in vaccinology. Nature Reviews Drug Discovery. 17 (4): 261-279. doi: 10.1038/nrd.2017.243
18. Kowalczyk A, Doener F, Zanzinger K, Noth J, Baumhof P, Fotin-Mleczek M, Heidenreich R (2016) Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 34 (33): 3882-3893. doi: 10.1016/j.vaccine.2016.05.046
19. Huang Q, Yan J (2021) SARS-CoV-2 virus: vaccines in development. Fundamental Research. 1 (2): 131-138. doi: 10.1016/j.fmre.2021.01.009
20. Hofman K, Shenoy GN, Chak V, Balu-Iyer SV (2021) Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunological Investigations. 50 (7): 743-779. doi: 10.1080/08820139.2021.1904977
21. Mallapaty BS, Callaway E, Kozlov M, Ledford H, Noorden R Van (2021) How COVID vaccines shaped 2021 in eight powerful charts. Nature. 600 (7890): 580-583. doi: 10.1038/d41586-021-03686-x
22. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (2022) Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases. 3099 (22): 1-10. doi: 10.1016/S1473-3099(22)00320-6
23. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome Nj, Huppert A, O'Brain KL, Smith PG, Wilder-smith A, Zeger S, Knoll MD, Patel MK (2022) Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet. 399 (10328): 924-944. doi: 10.1016/S0140-6736(22)00152-0
24. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Suárez P, García-Escorza H, Araos R (2021) Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. The New England Journal of Medicine. 385 (10): 875-884. doi: 10.1056/nejmoa210771
25. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT (2019) The how’s and what’s of vaccine reactogenicity. npj Vaccines. 4 (1): 39. doi: 10.1038/s41541-019-0132-6
26. Almufty HB, Mohammed SA, Abdullah AM, Merza MA (2021) Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 15 (5): 102207. doi: 10.1016/j.dsx.2021.102207
27. Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, Klugar M (2021) Prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in Turkey. Journal of Clinical Medicine. 10 (12): 2629. doi: 10.3390/jcm10122629
28. Al-Zawam MS, Abuleid KM, Al-Zawam MS, Ashour RA (2022) Prevalence of reactogenicity of COVID-19 vaccine among Libyan adults: a cross - sectional study. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2 (4): 48-53. doi: 10.5281/zenodo.7479756
29. Fidalgo ÁM (2005) Mantel-Haenszel methods. Encyclopedia of statistics in behavioral science. 3: 1120-1126. ISBN: 9780470860809. doi.org/10.1002/0470013192.bsa364
30. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, MMerino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas LS, Molteni E, Graham MS, Modat M, Joshi AD, Mangino M, Hammers A, Goodman AL, Chan AT, Wolf J, Steves CJ, Valdes AM, Ourselin S, Spector TD (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. The Lancet Infectious Diseases. 21 (7): 939-949. doi: 10.1016/S1473-3099(21)00224-3
31. Alemayehu A, Demissie A, Yusuf M, Abdullahi Y, Abdulwehab R, Oljira L, Feleke D (2022) COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study. SAGE Open Medicine. 10: 1-9. doi: 10.1177/20503121221108616
32. Al Bahrani S, Albarrak A, Alghamdi OA, Alghamdi MA, Hakami FH, Al Abaadi AK, Alkhrashi SA, Alghamdi MY, Almershad MM, Alenazi MM, El-Gezery MH, Jebakumar AZ, Al-Tawfiq JA (2021) Safety and reactoge- nicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia. International Journal of Infectious Diseases. 110: 359-362. doi: 10.1016/j.ijid.2021.07.052
33. Abbas S, Abbas B, Amir S, Wajahat M (2021) Evaluation of adverse effects with COVID-19 vaccination in Pakistan. Pakistan Journal of Medical Sciences. 37 (7): 1959-1964. doi: 10.12669/pjms.37.7.4522
34. Nurzak AN, Iqbal M, Yunus A, Wahyuni DF (2022) The evaluation of adverse effects of Sinovac® COVID-19 vaccine after receiving the first dose - Maros Health Center, December 2021. Journal of Pharmaceutical Negative Results. 13 (01): 78-83. doi: 10.47750/pnr.2022.13.S01.10

Citation :

Alzawam MS, Hasan FO (2023) Factors associated with the inflammatory immune response induced by COVID-19 vaccines among adults. Mediterr J Pharm Pharm Sci. 3 (1): 12-18. [Article number: 99]. https://doi.org/10.5281/zenodo.7771333